Yuichi Hattori


Affiliation: University of Toyama
Country: Japan


  1. Sakai M, Suzuki T, Tomita K, Yamashita S, Palikhe S, Hattori K, et al. Diminished responsiveness to dobutamine as an inotrope in mice with cecal ligation and puncture-induced sepsis: attribution to phosphodiesterase 4 upregulation. Am J Physiol Heart Circ Physiol. 2017;312:H1224-H1237 pubmed publisher
  2. Sakata K, Kondo T, Mizuno N, Shoji M, Yasui H, Yamamori T, et al. Roles of ROS and PKC-βII in ionizing radiation-induced eNOS activation in human vascular endothelial cells. Vascul Pharmacol. 2015;70:55-65 pubmed publisher
  3. Hattori Y, Hattori K, Suzuki T, Palikhe S, Matsuda N. Nucleic-acid based gene therapy approaches for sepsis. Eur J Pharmacol. 2018;833:403-410 pubmed publisher
  4. Tomita K, Takashina M, Mizuno N, Sakata K, Hattori K, Imura J, et al. Cardiac fibroblasts: contributory role in septic cardiac dysfunction. J Surg Res. 2015;193:874-87 pubmed publisher
    ..We suggest that cardiac fibroblasts are of pathogenetic importance in inflammation and fibrosis in the heart during sepsis, leading to cardiac dysfunction that would affect the outcome of sepsis syndrome. ..
  5. Ohashi W, Hattori K, Hattori Y. Control of Macrophage Dynamics as a Potential Therapeutic Approach for Clinical Disorders Involving Chronic Inflammation. J Pharmacol Exp Ther. 2015;354:240-50 pubmed publisher
    ..Controlling the macrophage dynamics to affect the pathologic states is considered to be an important therapeutic approach for many clinical disorders involving chronic inflammation. ..
  6. Yamashita S, Suzuki T, Iguchi K, Sakamoto T, Tomita K, Yokoo H, et al. Cardioprotective and functional effects of levosimendan and milrinone in mice with cecal ligation and puncture-induced sepsis. Naunyn Schmiedebergs Arch Pharmacol. 2018;: pubmed publisher
    ..This study represents that levosimendan and milrinone have cardioprotective properties but provide different advantages and drawbacks to cardiac inflammation/dysfunction in sepsis. ..
  7. Sakamoto T, Ohashi W, Tomita K, Hattori K, Matsuda N, Hattori Y. Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-?B from the Toll-like receptor signaling pathways. Int Immunopharmacol. 2018;62:120-131 pubmed publisher
    ..The therapy to specifically intervene in this pathway may be potentially beneficial for the prevention of different inflammatory disorders. ..
  8. Abdelzaher L, Imaizumi T, Suzuki T, Tomita K, Takashina M, Hattori Y. Astaxanthin alleviates oxidative stress insults-related derangements in human vascular endothelial cells exposed to glucose fluctuations. Life Sci. 2016;150:24-31 pubmed publisher
    ..Taken together, our results suggest that astaxanthin can protect vascular endothelial cells against glucose fluctuation by reducing ROS generation. ..
  9. Hattori M, Yamazaki M, Ohashi W, Tanaka S, Hattori K, Todoroki K, et al. Critical role of endogenous histamine in promoting end-organ tissue injury in sepsis. Intensive Care Med Exp. 2016;4:36 pubmed
    ..In the setting of sepsis, histamine, through activation of H1- and H2-receptors, serves as an aggravating mediator to contribute to the development of sepsis-driven major end-organ failure. ..

More Information


  1. Hattori Y, Hattori K, Matsuda N. Regulation of the Cardiovascular System by Histamine. Handb Exp Pharmacol. 2017;241:239-258 pubmed publisher
  2. Kambara K, Ohashi W, Tomita K, Takashina M, Fujisaka S, Hayashi R, et al. In vivo depletion of CD206+ M2 macrophages exaggerates lung injury in endotoxemic mice. Am J Pathol. 2015;185:162-71 pubmed publisher
    ..Our results indicate a critical role of CD206-positive pulmonary macrophages in triggering inflammatory cascade during endotoxemic lung inflammation. ..
  3. Hattori Y, Hattori K, Suzuki T, Matsuda N. Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges. Pharmacol Ther. 2017;177:56-66 pubmed publisher
    ..This review article provides an overview of possible pathogenic mechanisms underlying the development of multiple organ dysfunction in sepsis and discusses pharmacological agents regarded as promising in treatment of this disorder. ..
  4. Misawa H, Ohashi W, Tomita K, Hattori K, Shimada Y, Hattori Y. Prostacyclin mimetics afford protection against lipopolysaccharide/d-galactosamine-induced acute liver injury in mice. Toxicol Appl Pharmacol. 2017;334:55-65 pubmed publisher
    ..Our findings point to PGI2 mimetics, especially ONO-1301, as a potential novel therapeutic modality for the treatment of acute liver injury. ..